Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8210553 | International Journal of Radiation Oncology*Biology*Physics | 2018 | 10 Pages |
Abstract
ROs are less likely than other specialties to lead trials that use RT in combination with drug therapy or surgery and more likely to lead trials supported by nonindustry, non-NIH funding. This suggests a need for ROs to lead multimodality trials and to consider opportunities to interact with industry. As NIH resources decrease, alternative funding is needed to support innovation, particularly in in RT-alone trials.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Nicholas J. MD, Nastaran MPH, Bhupendra MS, Paul J. ScD, Paul L. MD, Jonathan D. MD, MPhil, MPH, Roy B. MD, PhD, Danielle N. MD, MPH,